免疫检查点及PD-1/PD-L1抑制药在肿瘤免疫诊断治疗中的应用  

Application of immune checkpoint and PD-1/PD-L1 inhibitors in antitumor immune diagnosis & treatment

作　　者：王冬艳[1] 华欣[2] 张志峰 叶记林[1] 季琰[1] 

机构地区：[1]扬州职业大学医学院,江苏扬州225009 [2]江苏省苏北人民医院

出　　处：《实用医药杂志》2018年第3期269-271,275,共4页Practical Journal of Medicine & Pharmacy

基　　金：2016年江苏省卫计委科研资助项目(J201613)

摘　　要：程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)单克隆抗体为代表的免疫检查点抑制药在肿瘤治疗领域取得了巨大的成功。故对免疫检查点抑制药在肿瘤免疫中的作用进行概述,并分析了免疫检查点抑制药的研究热点PD-1/PD-L1通路在抗肿瘤免疫的治疗意义,再对目前PD-1/PD-L1抑制药在诊断、治疗和预后中的应用调查,在此基础上分析PD-1/PD-L1抑制药进一步应用需要研究的问题,以期为PD-1/PD-L1抑制药进一步应用提供研究参考。Anti-programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1)monoclonal antibody as the representative of the immune checkpoint inhibitor has achieved great success in the treatment of cancer.The role of immunological examination in tumor immunity inhibitors are summarized in this review,and treatment significance of the immune checkpoint inhibiting PD-1/PD-L1 pathway is analysed;current PD-1/PD-L1 inhibitors applied in the diagnosis,treatment and prognosis at present are investigated on which the needed research relevant issnes of further application are analysed,in order to provide the reference for further application of PD-1/PD-L1 inhibitor.

关 键 词：抗肿瘤免疫 免疫检查点 程序性死亡受体-1/程序性死亡配体-1(PD-1/PD-L1)抑制药 

分 类 号：R392.9[医药卫生—免疫学]